There were 648 patients enrolled in the study (216 cases and 432 controls). Viral clearance (VC) was observed in 490 patients (75.6%), with a median time of 25 (IQR 16– 34) days. Overall, time to VC was similar between cases and controls (p = 0.519). However, time to VC was different when considering both Remdesivir (RDV) treatment status and age (p = 0.007). A significant finding was also observed when considering both RDV treatment status and P/F values at admission (p = 0.007). A multivariate analysis showed that VC was associated with a younger age (aHR = 0.990, 95% CI 0.983– 0.998 per every 10-year increase in age; p = 0.009) and a higher baseline P/F ratio (aHR=1.275, 95% CI 1.029– 1.579; p=0.026), but not with RDV treatment status.
Time to VC was similar in cases and controls. However, there was a benefit associated with using RDV in regard to time to VC in younger patients and in those with a loe respiratory efficiency (P/F ratio ≤ 200 mmHg) at hospital admission.
Spagnuolo V , Voarino M, Tonelli M , Galli L, Poli A, Bruzzesi E, Racca S, Clementi N , Oltolini C, Tresoldi M, Rovere Querini P, Dagna L , Zangrillo A, Ciceri F, Clementi M, Castagna A (2022) Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study. Drug Design, Development and Therapy 16, 3645-3654. https://doi.org/10.2147/DDDT.S369473